Harrow (HROW) Notes Payables (2011 - 2025)

Harrow (HROW) posted quarterly Notes Payables of $183.6 million for Q2 2025, up 69.53% quarter-over-quarter from $108.3 million in Q1 2025.

Harrow (HROW) Notes Payables (2011 - 2025) Analysis & Trends

Harrow's Notes Payables history runs 10 years deep, the most recent figure standing at $183.6 million for Q2 2025.

In Q2 2025, Notes Payables changed N/A year-over-year to $183.6 million; the TTM figure through Jun 2025 stood at $183.6 million (changed N/A YoY), while the FY2020 annual figure was $3.9 million, up 119.98% from the prior year.
Notes Payables for Q2 2025 stood at $183.6 million, up from $108.3 million in the prior quarter.
The five-year high for Notes Payables was $183.6 million in Q2 2025, with the low at -$3.7 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-
10	Harrow	1.55 Bn	1.46 Bn	50.36 Mn

Download Data